SB
TAK icon

Strategic Blueprint’s Takeda Pharmaceutical TAK Stock Holding History

Strategic Blueprint’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-885
Closed -$15K – 380
2019
Q3 		$15K Buy
+885
New +$15.3K 0.01% 262

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Strategic Blueprint's TAK Position: Q4 2019 in Review

Strategic Blueprint sold out of Takeda Pharmaceutical (TAK) in Q4 2019, closing a stake of 885 shares — an estimated $15K sold.

Strategic Blueprint first reported a position in TAK in Q3 2019 and held it in 1 quarter. The position peaked at $15K in Q3 2019. 339 funds tracked by Wall St. Rank hold TAK as of Q4 2019.

  • Strategic Blueprint reported no remaining Takeda Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • Strategic Blueprint sold 885 Takeda Pharmaceutical shares in Q4 2019, an estimated $15K.
  • Strategic Blueprint first reported a position in Takeda Pharmaceutical in Q3 2019 and held it in 1 quarter.
  • Strategic Blueprint's Takeda Pharmaceutical position peaked at $15K in Q3 2019.
  • 339 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2019.

Based on Strategic Blueprint's 13F filing for Q4 2019, filed 10 Jan 2020.